← Leaderboards
Edgar A Jaimes
University Of Miami School Of Medicine
$2,950,402
Attributed
$4,419,252
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $753.4K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,419,252 · 5
VA$0 · 2
By mechanism
R01$3,670,319 · 3
R03$443,089 · 1
R43$305,844 · 1
I01$0 · 1
IP1$0 · 1
Top collaborators
- Anupam Agarwal4 shared
- Yabing Chen4 shared
- Daniel Alan Heller4 shared
- Paul W. Sanders4 shared
- Yan-Ting E. Shiu4 shared
- Chintan H Kapadia1 shared
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Andrea Malaspina$1,153,959
- Mary-Louise Rogers$1,153,959
Others in their field
Top investigators on “Morbidity - Disease Rate”
- Marco Pahor · Wake Forest University Health Sciences$29,421,775
- A Benedict Cosimi · Massachusetts General Hospital$17,236,164
- Judith S. Currier · University Of California Los Angeles$11,229,603
- Andrea Jenay Ruff · Johns Hopkins University$10,896,035
- Lucile L Adams-Campbell · Howard University$10,384,616
- Michael K Ong · University Of California Los Angeles$9,898,332
Research focus
Morbidity - Disease RatePreventUnited StatesChronic Kidney FailureBlood VesselsPathogenesisRattusReactive Oxygen SpeciesMolecularIn VitroOrganAnimalsDepositionAffectKidneyImmunohistochemistryTissuesPathway InteractionsBaseMediatingMediator Of Activation ProteinPrevalenceMortalityGenerations
Grant awards (21)
Nanotechnology as a therapeutic approach in arteriovenous fistula maturation$417,075
R01 · FY2024 · DK
Nanotechnology as a therapeutic approach in arteriovenous fistula maturation$434,453
R01 · FY2023 · DK
Nanotechnology as a therapeutic approach in arteriovenous fistula maturation$434,453
R01 · FY2022 · DK
Nanotechnology as a therapeutic approach in arteriovenous fistula maturation$447,578
R01 · FY2021 · DK
Efficacy and pharmacokinetic assessment of renal-targeted therapy in a pig model of cisplatin induced acute kidney injury.$305,844
R43 · FY2021 · DK
Renal tubule-specific nanotherapeutics for acute kidney injury$269,400
R01 · FY2020 · DK
Renal tubule-specific nanotherapeutics for acute kidney injury$269,400
R01 · FY2019 · DK
Renal tubule-specific nanotherapeutics for acute kidney injury$257,550
R01 · FY2018 · DK
Novel Regulators of Vascular Disease$0
IP1 · FY2016 · VA
Novel Regulators of Vascular Disease$0
IP1 · FY2015 · VA
Novel Regulators of Vascular Disease$0
IP1 · FY2014 · VA
ETS-1 and Vascular and Renal Injury in Salt Sensitive Hypertension$0
I01 · FY2014 · VA · contact PI
Novel Regulators of Vascular Disease$0
IP1 · FY2013 · VA
ETS-1 and Vascular and Renal Injury in Salt Sensitive Hypertension$0
I01 · FY2013 · VA · contact PI
ETS-1 and Vascular and Renal Injury in Salt Sensitive Hypertension$0
I01 · FY2012 · VA · contact PI
ETS-1 and Vascular and Renal Injury in Salt Sensitive Hypertension$0
I01 · FY2011 · VA · contact PI
Nicotine and Chronic Kidney Disease$573,010
R01 · FY2010 · ES · contact PI
Nicotine and Chronic Kidney Disease$567,400
R01 · FY2009 · ES · contact PI
Glomerular COX-2 in Hypertensive Renal Disease$143,649
R03 · FY2007 · DK · contact PI
Glomerular COX-2 in Hypertensive Renal Disease$147,940
R03 · FY2006 · DK · contact PI
Glomerular COX-2 in Hypertensive Renal Disease$151,500
R03 · FY2005 · DK